Altered Expression of CYSLTR1 is Associated With Adverse Clinical Outcome in Triple Negative Breast Tumors: An In Silico Approach

• Published in: European journal of breast health 2023-04, Vol.19 (2), p.148-158
• Main Authors: Céspedes, Andrés Galindo, Conceição, Mércia Patrícia Ferreira, de Bastos, Daniel Rodrigues, de Grazia, Gabriela Ávila, Leite, Jean Michel Rocha Sampaio, do Nascimento, Renan Gomes, Ferreira, Matthew Thomas, Lopez, Rossana Mendoza
• Format: Article
• Language: English
• Subjects: cysltr1; leukotriene; mediators of inflammation; Original; triple-negative breast cancer
• ISSN: 2587-0831; 2587-0831
• DOI: 10.4274/ejbh.galenos.2023.2022-12-10

Triple negative breast cancer (TNBC) has high relapse rates due to dysregulated inflammatory signaling pathways and significant changes in the tumor microenvironment, probably influencing the failure of several therapies. The Cysteinyl Leukotriene Receptor 1 (CYSLTR1), a leukotriene modulator of inflammation, has been shown to play an important role in cancer pathogenesis and survival but few studies have been reported on its role in breast cancer. The present work was conducted using publicly available platforms that have omics data to assess the clinical potential of CYSLTR1 expression and its prognostic validation in large cohorts of samples from breast cancer patients. Web platforms containing clinical information, RNA-seq and protein data were selected to perform analyses of the potential marker CYLSTR1. Added together, the platforms included modules for correlation, expression, prognosis, drug interactions, and construction of gene networks. Kaplan-Meier curves revealed that reduced levels of CYSLTR1 corresponded to an unfavorable outcome for overall survival (